Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.
Type:
Grant
Filed:
August 10, 1998
Date of Patent:
September 19, 2000
Assignee:
ALZA Corporation
Inventors:
Patrick S. L. Wong, Liang-Chang Dong, David E. Edgren, Felix Theeuwes, Phyllis I. Gardner, Francisco Jao, Jason J. Wan
Abstract: An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule containing a beneficial agent and an osmotic agent which swells on contact with water causing the release of the beneficial agent over time. The osmotic delivery system has a membrane plug which allows water to pass through the plug from an exterior of the capsule while preventing the compositions within the capsule from passing out of the capsule. A delivery rate for delivery of the beneficial agent from the implant capsule is controlled by varying a core diameter of the membrane plug within a constant diameter capsule. The membrane plug has a variable water permeation rate depending on an extent to which the membrane plug is constrained by the capsule walls.
Type:
Grant
Filed:
July 24, 1998
Date of Patent:
September 5, 2000
Assignee:
ALZA Corporation
Inventors:
Guohua Chen, Scott Lautenbach, Keith Dionne, Lawton Hom
Abstract: An electrotransport delivery device (410) includes control circuitry for discontinuously delivering a beneficial agent (eg, a drug) through a body surface (eg, skin 400). For example, the device may be the type which is manually activated by the patient or other medical personnel to activate electrotransport drug delivery. Once electrotransport delivery has been activated, a timer (221) counts a transition interval, typically about one minute, during which the device is allowed to operate and the impedance of the body surface (400) is allowed to stabilize. Thereafter, the electrotransport current and voltage are then monitored and compared to predetermined limits. Allowing for the transition interval permits tighter tolerances in monitoring the applied current.
Type:
Grant
Filed:
June 24, 1997
Date of Patent:
July 18, 2000
Assignee:
ALZA Corporation
Inventors:
Larry A. McNichols, John D. Badzinski, Ronald P. Haak
Abstract: A two-part electrotransport drug delivery device (20) is comprised of a controller (22) which has a plurality of different electronic outputs. The controller (22) is adapted to be mechanically and electrically coupled to a plurality of different drug-containing units (24). Each drug unit (24) includes a means (40, 42, Rx, Cx) for signaling the controller (22). The signal is read by the controller (22) and a predetermined electronic output is thereby selected and applied through the drug unit (24) in order to deliver the drug contained therein by electrotransport. The signal sent by the drug unit (24) to the controller (22) may be an optical signal (e.g., reflected light), a signal sent by an electro-mechanical connector, an electrical signal (e.g., resistance or capacitance), a magnetic signal or a metal detector sensing signal.
Type:
Grant
Filed:
March 9, 1998
Date of Patent:
July 11, 2000
Assignee:
ALZA Corporation
Inventors:
Susan A. Johnson, Gary A. Lattin, Larry A. McNichols
Abstract: An electrotransport composition comprises at least one C.sub.2 -C.sub.4 lower alcohol, unsaturated derivatives thereof, or mixtures thereof, and at least one C.sub.8 -C.sub.4 higher alcohol, unsaturated derivatives thereof, or mixtures thereof. An electrotransport device and a method of increasing transdermal electrotransport flux utilize the composition of the invention for delivering pharmaceutically-acceptable agents across a body surface such as skin.
Type:
Grant
Filed:
December 14, 1998
Date of Patent:
July 4, 2000
Assignee:
ALZA Corporation
Inventors:
J. Richard Gyory, Jane Yieh, James A. Huntington, Michel Cormier
Abstract: A device (3) comprising a sheet member (6) having a plurality of microprotrusions (4) for penetrating the skin and a substantially incompressible agent reservoir housing (15) contacting and extending across the sheet member (6) for transmitting a hold-down force applied the sheet member (6) to maintain the microprotrusions (4) in skin-piercing relation to the skin, even during and after normal patient body movement.
Type:
Grant
Filed:
December 9, 1998
Date of Patent:
July 4, 2000
Assignee:
ALZA Corporation
Inventors:
Joseph Creagan Trautman, Michel J. N. Cormier, Hyunok Lynn Kim, Michael G. Zuck
Abstract: An opiate analgesic composition and a non-opiate analgesic composition are disclosed for delivering an analgesic in either embodiment to a patient in need of relief from pain. The analgesics are present optionally with a nonionic surfactant and with an osmotic composition comprising a carbonate or bicarbonate for delivering the opiate analgesic and non-opiate analgesic from a dosage form.
Type:
Grant
Filed:
June 15, 1999
Date of Patent:
June 20, 2000
Assignee:
Alza Corporation
Inventors:
Sonya Merrill, Atul D. Ayer, Paul M. Hwang, Anthony L. Kuczynski, Nils W. Ahlgren, Deborah J. Johnson
Abstract: A method is provided for preparing drug formulations suitable for electrotransport drug delivery. The drug to be delivered, present in salt form, is contacted with an ion exchange material prior to incorporation into the reservoir (26) of an electrotransport delivery system (10). In this way, the drug salt is partially or completely neutralized. This technique is useful for adjusting the pH of the drug formulation without incorporating extraneous materials, e.g., competing ions or the like, into the reservoir (26).
Abstract: This invention relates to stable liquid aqueous formulations of peptide compounds at high concentrations. These stable formulations comprise at least about 10% peptide in water. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
Type:
Grant
Filed:
February 11, 1999
Date of Patent:
May 30, 2000
Assignee:
Alza Corporation
Inventors:
Cynthia L. Stevenson, Sally A. Tao, Steven J. Prestrelski, James B. Eckenhoff, deceased, Jeremy C. Wright, John J. Leonard, Jr.
Abstract: This invention relates to stable non-aqueous protic formulations of peptide compounds. These stable formulations comprise peptide in non-aqueous protic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
Type:
Grant
Filed:
April 16, 1999
Date of Patent:
May 23, 2000
Assignee:
Alza Corporation
Inventors:
Cynthia L. Stevenson, Sally A. Tao, Steven J. Prestrelski, James B. Eckenhoff, Jeremy C. Wright, John J. Leonard, Jr.
Abstract: An electrotransport drug-containing composition is provided. The composition includes a drug to be delivered through a body surface (eg, skin) of a patient, and a permeation enhancer which is solid or semisolid at temperatures typically encountered during storage of pharmaceuticals (eg, temperatures up to at least about 25.degree. C.). The composition of the invention may be applied from a device 10 suitable for electrotransport delivery. A method for increasing electrotransport agent delivery rate and reducing body surface resistance relies on applying the composition of the invention to the body surface, and applying an electric current through the composition and the body surface.
Abstract: A device (2) comprising a sheet member (6) having a plurality of microprotrusions (4) extending from a bottom edge (5) for penetrating the skin of a patient. The sheet member (6) when in use being oriented in an approximately perpendicular relation to the patient's skin.
Abstract: An electrotransport apparatus using dispersed ion exchange material (19,83) is disclosed. The ion exchange material (19,83) may be dispersed in either the donor electrode assembly (10), the counter electrode assembly (10) or both electrode assemblies. The dispersed ion exchange material (83) comprises mobile ionic species (84-2) and substantially immobile ionic species (P). The dispersed ion exchange material (83, 84-2) interacts with competitive species (86) generated during electrotransport to render those species substantially immobile (87). Electrotransport devices exhibiting reduced polarization are also disclosed.
Type:
Grant
Filed:
September 26, 1997
Date of Patent:
April 11, 2000
Assignee:
ALZA Corporation
Inventors:
J. Bradley Phipps, Lyn C. Moodie, J. Richard Gyory, Felix Theeuwes
Abstract: Pharmaceutical hydrogel formulations containing polyvinyl alcohol are provided. The formulations may serve as rug reservoirs in electrotransport drug delivery systems or passive transdermal systems, or they may be used in a variety of other types of dosage forms, e.g., capsules, suppositories, aerosols, and the like. With these formulations, there is virtually no syneresis encountered upon long term storage, an advantage that derives from selecting the quantity of polyvinyl alcohol in the gel to correspond to the polymer's degree of hydrolysis.
Type:
Grant
Filed:
December 9, 1997
Date of Patent:
March 21, 2000
Assignee:
Alza Corporation
Inventors:
Subramanian S. Venkatraman, Thomas O. Murdock, Stephanus Pudjijanto
Abstract: A dosage form and a method are disclosed and claimed for administering a drug in a sustained and constantly ascending rate per unit time to provide an intended therapeutic effect while concomitantly lessening the development of unwanted effects.
Type:
Grant
Filed:
July 31, 1997
Date of Patent:
March 7, 2000
Assignee:
ALZA Corporation
Inventors:
Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks
Abstract: An electrotransport device (10) for delivering therapeutic agents includes an adjustable voltage boost multiple controller (100, 200) for boosting the voltage from a power source (102, 202) to a working voltage V.sub.w having a value just sufficient to provide the desired therapeutic current level I.sub.I through the electrodes (108, 112), at least one of which contains the therapeutic agent to be delivered.
Type:
Grant
Filed:
September 29, 1997
Date of Patent:
March 7, 2000
Assignee:
Alza Corporation
Inventors:
Thomas A. Riddle, Larry A. McNichols, John D. Badzinski
Abstract: An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.
Type:
Grant
Filed:
February 3, 1999
Date of Patent:
December 28, 1999
Assignee:
Alza Corporation
Inventors:
David J. Enscore, Patricia S. Campbell, Diane Nedberge, Richard D. Frame
Abstract: The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a transdermal drug delivery device comprising a matrix adapted to be placed in drug- and- permeation enhancer- transmitting relation with a skin site. The matrix contains sufficient amounts of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compositions and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers.
Abstract: Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.
Type:
Grant
Filed:
December 18, 1996
Date of Patent:
December 14, 1999
Assignee:
Alza Corporation
Inventors:
Su I Yum, Melinda K. Nelson, Patricia S. Campbell